kotak-logo
Lincoln Pharmaceuticals Share Price

Lincoln Pharmaceuticals Share Price

616.75
-6.15 (-0.99%)
LINCOLN • 06 Mar, 2026 | 03:29 PM
Buywith MTF at 1x leverage

1Y Annualised Return

10.78%

3Y Annualised Return

22.19%

5Y Annualised Return

21.95%

10Y Annualised Return

14.62%

Lincoln Pharmaceuticals Stock Performance

1W Return-2.27
1Y Return9.68
Today's Low616
Prev. Close622.90
Mkt Cap (Cr.)1,235.33
1M Return34.13
3Y Return82.55
52-Week High677
Open622.85
PE Ratio14.07
6M Return10.39
Today's High622.9
52-Week Low440
Face Value10

Lincoln Pharmaceuticals Company background

Founded in: 1995
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes antiinfective, respiratory system, gynecology, cardio CNS, antidiabetic, anti malaria, among others.The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake inhouse testing of its products for better quality control and RD. It came out with a public issue in Feb.96 to partfinance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 202122, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022. The Company commenced commercial production in Mehsana in FY 2025.

Lincoln Pharmaceuticals Financial Highlights


For the full year FY2025–2026, revenue reached ₹645.71 crore and profit touched at ₹82.35 crore.

Lincoln Pharmaceuticals Share Price Today


As of 7 Mar 2026, Lincoln Pharmaceuticals share price is ₹616.8. The stock opened at ₹622.8 and had closed at ₹622.9 the previous day. During today’s trading session, Lincoln Pharmaceuticals share price moved between ₹616.00 and ₹622.90, with an average price for the day of ₹619.45. Over the last 52 weeks, the stock has recorded a low of ₹440.00 and a high of ₹677.00. In terms of performance, Lincoln Pharmaceuticals share price has increased by 10.4% over the past six months and has increased by 10.78% over the last year.
Read More
Lincoln Pharmaceuticals SIP Return Calculator
5,000
Over the past
Total Investment of ₹3,00,000
Monthly SIP of 5,000 would have become 5,47,537 in 5 years with a gain of 2,47,537 (+82.51%)
View details of Market Depth

Lincoln Pharmaceuticals Fundamental

Market Cap (in crs)

1,235.33

Face Value

10

Turnover (in lacs)

73.68

Key Metrics

Qtr Change %
40.17% Gain from 52W Low
25.1
Dividend yield 1yr %
Below industry Median
0.3

Lincoln Pharmaceuticals Key Financials

View more
Loading chart...
Lincoln Pharmaceuticals Quarterly Revenue
Lincoln Pharmaceuticals Yearly Revenue
Lincoln Pharmaceuticals Quarterly Net Profit/Loss
Lincoln Pharmaceuticals Yearly Net Profit/Loss

Lincoln Pharmaceuticals Result Highlights

  • Lincoln Pharmaceuticals Ltd reported a 6.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.7%.

  • Its expenses for the quarter were up by 3.5% QoQ and 15.7% YoY.

  • The net profit increased 43.1% QoQ and increased 37.7% YoY.

  • The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 14.28 during Q3 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lincoln Pharmaceuticals Technical Analysis

Moving Averages Analysis
616.75
Current Price
Bullish Moving Averages
13
Bearish Moving Averages
3
Day EMA5
620.00
Day EMA10
615.90
Day EMA12
612.10
Day EMA20
593.40
Day EMA26
580.50
Day EMA50
549.70
Day EMA100
534.50
Day EMA200
545.10
Delivery & Volume
Loading chart...

Day

61.30%

Week

57.10%

Month

42.00%

Delivery & Volume

618.55
Pivot
Resistance
First Resistance
621.10
Second Resistance
625.45
Third Resistance
628
Support
First Support
614.20
Second support
611.65
Third Support
607.30
Relative Strength Index
63.02
Money Flow Index
48.83
MACD
31.59
MACD Signal
34.79
Average True Range
26.41
Average Directional Index
58.08
Rate of Change (21)
30.93
Rate of Change (125)
12.14
Compare

Lincoln Pharmaceuticals Shareholding Pattern

Promoter
49.8%
Foreign Institutions
4.7%
Public
45.5%

Lincoln Pharmaceuticals Latest News

23 FEB 2026 | Monday
13 FEB 2026 | Friday
13 FEB 2026 | Friday

Please be aware that Lincoln Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.